| Literature DB >> 35873549 |
Wei Tan1, Yunyan Wang1, Hongmei Dai2, Junhui Deng1, Zhifen Wu1, Lirong Lin1, Jurong Yang1.
Abstract
At present, there is no effective drug for the treatment of renal fibrosis; in particular, a safe and effective treatment for renal fibrosis should be established. Cordyceps has several medical effects, including immunoregulatory, antitumor, anti-inflammatory, and antioxidant effects, and may prevent kidney, liver, and heart diseases. Cordyceps has also been reported to be effective in the treatment of renal fibrosis. In this paper, we review the potential mechanisms of Cordyceps against renal fibrosis, focusing on the effects of Cordyceps on inflammation, oxidative stress, apoptosis, regulation of autophagy, reduction of extracellular matrix deposition, and fibroblast activation. We also discuss relevant published clinical trials and meta-analyses. Available clinical studies support the possibility that Cordyceps and related products provide benefits to patients with chronic kidney diseases as adjuvants to conventional drugs. However, the existing clinical studies are limited by low quality and significant heterogeneity. The use of Cordyceps and related products may be a potential strategy for the treatment of renal fibrosis. Randomized controlled trial studies with good methodological quality, favorable experimental design, and large sample size are needed to evaluate the efficacy and safety of Cordyceps.Entities:
Keywords: Chinese herbal medicine; chronic kidney disease; cordyceps; mechanism; renal fibrosis
Year: 2022 PMID: 35873549 PMCID: PMC9304961 DOI: 10.3389/fphar.2022.932172
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.988
Mechanisms of Cordyceps and related products against renal fibrosis.
| Compound/extract | Animal/cell | Model/inducer | Outcomes | Targets/pathway | Mode of action | References |
|---|---|---|---|---|---|---|
| CCP | SD rats | HFD + STZ | TNF-α↓, IL-1β↓, IL-6↓ | Blocking the TLR4/NF-κB and TGF-β1/Smad signaling pathway | Anti-inflammatory; regulation of dysbiosis of gut microbiota |
|
| Inflammatory cell infiltration↓ | ||||||
| CTGF↓, MMP-2↓, HYP↓ | ||||||
| Collagen deposition↓ | ||||||
| a-SMA and Collagen I expression↓ | ||||||
| Regulation of dysbiosis of gut microbiota | ||||||
| NRK-52E Cells | LPS | TNF-α↓, IL-1β↓, IL-6↓ | ||||
| NRK-49F cells | TGF-β | Collagen I↓, Fibronectin↓, α-SMA↓ | ||||
| HEA | C57BL6/J mice | UUO | Integrity of renal parenchymal cells↑ | Inhibition of TGF-β1/Smad and NF-κB signaling pathways | Anti-inflammatory |
|
| Collagen deposition↓ | ||||||
| TGF-β1↓, α-SMA↓, collagen I↓, Fibronectin↓ | ||||||
| TNF-α↓, IL-6↓, IL-1β↓ | ||||||
| M1↓, M2↑ | ||||||
| RAW 264.7 cells | LPS | TNF-α↓,IL-1β↓, IL-10↑ | ||||
| NRK-49F cells | TGF-β | Fibronectin↓,α-SMA↓, collagen I | ||||
| HEA | SD rats | Alloxan monohydrate | TNF-α↓, IL-1β↓, IL-6↓ | Inhibition of TGF-β1 and NF-κB | Anti-inflammatory; antioxidative stress |
|
| SOD↑, CAT↑, GSH↑, MDA ↓ | ||||||
| Tubular necrosis↓, inflammatory infiltration↓, thickening of the membrane basement↓ | ||||||
| Cordycepin | HEK293T cells | — | IL-1 β↓, TNF-α↓ | Inhibition of TLR4/NF-κB pathway | Anti-inflammatory |
|
| Cordyceps cicadae/Paecilomyces cicadae | SD rats | 250 mg/kg adenine | MDA↓, GSH↓, SOD↑ | May be related to the downregulated PAI-1 | Antioxidative stress; anti-inflammatory |
|
| Kidney indices↓, the number of the glomerulus↑ | ||||||
| Interstitial inflammation in the proximal and distal convoluted tubules↓ | ||||||
| Ophiocordyceps Lanpingensis | C57BL/6 Mice | 0.25% adenine | Ameliorate the CKD pathological Changes | Inhibition of TLR4-mediated MAPK/NF-κB pathway | Antioxidative stress; anti-inflammatory Antiapoptosis |
|
| Recruitment of macrophages↓ | ||||||
| SOD↑, GSH-PX↑, ROS↓, MDA↓ | ||||||
| TNF-α↓, IL-1β↓, IL-10↑ | ||||||
| Apoptosis cells↓, BAX↓, Caspase-3↓, Caspase-9↓, Bcl-2↑ | ||||||
| Tissue fibrosis↓, TGF-β1 expression↓, α-SMA↓, collagen I↓ | ||||||
| HEA | HK-2 cells | NSAIDs diclofenac/meloxicam | ROS↓ | Regulates the GRP78/ATF6/PERK/IRE1α/CHOP pathway | Antioxidative stress; antiapoptosis |
|
| Apoptosis cells↓ | ||||||
|
| SD rats | HFD + STZ | SOD↑, GSH-px↑, ROS↓, MDA↓ | Phosphor-AKT↓ phosphor-GSK-3β↓ | Antioxidative stress; anti-inflammatory |
|
| Inflammatory infiltrate↓ | ||||||
|
| SHR/WK rats | SHR | Collagen deposition↓, a-SMA↓ | Inhibition of SIRT1/p53 pathway | Antiapoptosis |
|
| Primary human RPTEC | AngII | Apoptosis cells↓, Caspase-3↓ | ||||
| CMP | C57BL/6 mice | STZ | Collagen deposition↓ | — | Activation of autophagy; anti-inflammatory; antioxidative stress |
|
| CD68↓, IL-1β↓, IL-6↓, MCP-1↓ | ||||||
| Autophagosome↑ | ||||||
| Atg5↑, beclin1↑, LC3↑, p62↓ | ||||||
| GSH↑, MDA↓ | ||||||
|
| SHR/WK rats | SHR | Collagen deposition↓ | Activation of SIRT1/FOXO3a/ROS | Inhibition of autophagy; antioxidative stress |
|
| TGFβ1↓, α-SMA↓, fibronectin↓, collagen I↓ | ||||||
| Apoptosis cells↓ | ||||||
| LC3II↓, beclin-1↓, SQSTM1/p62↓ | ||||||
| SOD↑, MDA ↓ | ||||||
| NRK-52E cells | AngII/rapamycin | Collagen I↓, α-SMA↓ | ||||
| LC3II↓, beclin-1↓ | ||||||
| Nucleoside/nucleobase extract | C57BL/6 mice | STZ | Collagen deposition↓ | Phosphor-p38↓ phosphor-ERK↓ | Inhibition of EMT and ECM deposition |
|
| Fibronectin↓, collagen I↓ | ||||||
| E-cadherin↑, α-SMA↓ | ||||||
| HK-2 cells | HG | Morphological and phenotypic changes↓ | ||||
| E-cadherin↑, α-SMA↓ | ||||||
| Fibronectin↓, collagen I↓ | ||||||
| Ergosterol peroxide | NRK-49F cells | TGF-β1 | Renal fibroblast proliferation rate↓ | Blocking the phosphorylation of ERK1/2, p38, and JNK pathway | Ameliorates TGF-β1-induced activation of kidney fibroblasts |
|
| Fibronectin↓, a-SMA↓, vimentin↓, CTGF↓ | ||||||
| CmNo1 extract | C57BL/6J mice | HFD + STZ | Collagen IV↓ | TGF-β1↓ | Inhibition of collagen deposition |
|
|
| SD rats | 5/6 nephrectomy | Interstitial fibrosis↓ | Inhibition of TGF-β1/Smad pathway | Inhibition of EMT and ECM deposition |
|
| E-cadherin↑, α-SMA↓, FSP1↓ | ||||||
| TGF-β1↓, TβR1↓, TβR2↓, Smad2↓, Smad3↓, Smad7↑ | ||||||
| 3′-Deoxyadenosine | C57BL/6 mice | UUO | Collagen I↓, α-SMA↓ | Reduced phosphorylation and total Smads through transcriptional repression | Inhibition of ECM deposition |
|
| Interstitial myofibroblasts↓, fibrotic area↓ | ||||||
| NRK-52E | TGF-β/BMP-4 | Collagen I↓, collagen IV↓ | ||||
|
| SD rats | UUO | Interstitial collagen deposition Masson↓, α-SMA↓ | BAG3↓ | Inhibition of EMT and ECM deposition |
|
|
| C57BL/Ks mice | db/db diabetic | Interstitial fibrosis↓ | Metabolites of the TCA cycle, glycolysis, pentose phosphate pathway, pyrimidine metabolism, and purine metabolism↓ | Regulation of disturbed metabolome |
|
| TGF- β1↓, CTGF↓, VEGF↓, fibronectin↓, collagen I↓, collagen IV↓ |
HFD, high-fat diet; TNF, tumor necrosis factor; IL-1, interleukin 1; IL-6, interleukin 1; CTGF, connective tissue growth factor; MMP-2, matrix metalloproteinase-2; HYP, hydroxyproline; a-Smooth muscle actin, a-shape memory alloy; TLR4, Toll-like receptor 4; NF-κB, Nuclear factor-kappaB; TGF-β1, transforming growth factor beta1; SOD, superoxide dismutase; CAT, catalase; GSH, glutathione; MDA, malondialdehyde; ROS, reactive oxygen species; Bcl-2, B-cell chronic lymphocytic leukemia/lymphoma-2; BAX, Bcl-2-associated X protein; GRP78, glucose-regulated protein 78; ATF6, activating transcription factor 6; PERK, protein kinase R (PKR)-like endoplasmic reticulum kinase; IRE1α, inositol-requiring enzyme 1 alpha; CHOP, C/EBP homologous protein; SHR, spontaneously hypertensive; RPTEC, renal proximal tubular epithelial cells; WK, wistar-kyoto; SIRT1, Sirtuin-1; MCP-1, monocyte chemoattractant protein-1; Atg5, Autophagy Protein 5; LC3, light chain 3; SQSTM1, sequestosome1; FOXO3a, forkhead box class O3a; HG, high glucose; ERK, extracellular signal-regulated kinase; JNK, c-Jun N-terminal kinase; CmNo1, cordyceps militaris No.1; FSP1, ferroptosis suppressor protein 1; EMT, epithelial–mesenchymal transition; ECM, extracellular matrix; BAG3, Bcl-2-associated athanogene 3; VEGF, vascular endothelial growth factor; TCA, tricarboxylic acid.
Clinical studies with Cordyceps.
| Study type | N | Therapeutic arms | Disease | Duration | Outcomes | References |
|---|---|---|---|---|---|---|
| RCT | 98 | COG vs. CG | CKD late stage 3 or stage 4 | 3 months | In COG group |
|
| Inflammatory state and thickness of glomerular filtration membrane in renal tissue↑ | ||||||
| Urinal protein↓ BUN↓, creatinine↓, EGFR↑ ( | ||||||
| TG↓, TC↓, LDL-C↓, HDL-C↑ ( | ||||||
| Cys-C ↓, MPO ↓, MDA ↓, NO ↑, SOD ↑ ( | ||||||
| Study cohort | 160 | Bailing capsules + losartan vs. losartan | Diabetic glomerulosclerosis | — | In Bailing capsules + losartan group |
|
| ORR↑, 91.25% vs. 78.75% | ||||||
| DBP↓, SBP↓, Scr↓, BUN↓, 24 h UP↓, mALB↓, β2-MG↓,GFR↑ ( | ||||||
| TCM points↓ ( | ||||||
| SOD↑, ROS↓, 8-OHdG↓, hs-CRP↓, TGF-β1↓, SAA↓ ( | ||||||
| Review | 1746 | Cordyceps vs. placebo, no treatment, or conventional treatment | CKD | — | In Cordyceps group |
|
| Scr↓ (14 studies, 987 participants), Ccr↑ (6 studies, 362 participants), 24 h UP ↓ (4 studies, 211 participants) | ||||||
| Meta-analysis | 3955 | JSB capsules + ACEI/ARB vs. ACEI/ARB | Diabetic kidney disease | 28 days–4 weeks | In JSB combined with ACEI/ARB group |
|
| ORR↑ (OR 4.91; 95% CI 3.32–7.25) | ||||||
| 24 h UP↓, UAER↓, Scr↓, BUN↓ ( | ||||||
| SBP↓, DBP↓,FBG↓, HA1c↓, TC↓, TG↓ | ||||||
| Meta-analysis | 2198 | JSB + ARBs vs. ARBs | Early diabetic Nephropathy | 8–28 weeks | In JSB + ARBs group |
|
| ORR ↑ (OR 3.84; 95% CI: 2.37–6.24; | ||||||
| 24 h UTP↓, UAER↓, ACR↓, Cys-C↓, TG↓ ( | ||||||
| BUN↓ ( | ||||||
| Meta-analysis | 4288 |
| Diabetic kidney disease | 4–24 weeks | In |
|
| 24 h UP↓, UAER↓, MAU↓, CRP↓, TG↓, TC↓ ( | ||||||
| BUN↓, Scr↓ ( | ||||||
| SBP↓ ( | ||||||
| Meta-analysis | 1941 | Bailing capsules + control group treatment vs. routine treatment, and/or combined with Western medicine | Type 2 diabetic nephropathy | 4–24 weeks | In the group containing Bailing capsules |
|
| ORR ↑ (OR = 1.24; 95% CI: 1.11–1.38) | ||||||
| 24 h urine total protein↓, UAER↓, Scr↓, BUN↓ ( | ||||||
| RCT | 97 | HEA-enriched | — | 3 months | No differences in symptoms or side effects between participants. There was also no significant difference between baseline measurements and the final analysis of biochemical analysis, such as kidney function, liver function, and blood electrolytes |
|
COG, cordycepin group; CG, control group; GFR, glomerular filtration rates; TG, triglyceride; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, low-density lipoprotein cholesterol; Cys-C, cystatin-C; MPO, myeloperoxidase; MDA, malondialdehyde; NO, nitric oxide; SOD, superoxide dismutase; DBP, diastolic blood pressure; SBP, systolic blood pressure; Scr, serum creatinine; BUN, blood urea nitrogen; 24 h UP, 24 h urine protein; mALB, urine microalbumin; β2-MG, β2 microglobulin; TCM, traditional chinese medicine; ROS, reactive oxygen species; 8-OhdG, 8-hydroxydeoxyguanine; hs-CRP, hypersensitive C-reactive protein; TGF-β1, transforming growth factor β1; SAA, serum amyloid A; Ccr, creatinine clearance; FBG, fasting blood glucose; HA1c, hemoglobin A1c; JSB, jinshuibao; CI, confidence interval; MD, mean difference; ORR, overall response rate; ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; 24 h UTP, 24 h urinary total protein; UAER, urinary albumin excretion rate; ACR, albumin-to-creatinine ratio; MAU, microalbuminuria.